Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia

Reuters2026/08/17 01:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Unicycive outlined plans to resubmit its NDA for oxylanthanum carbonate, a 505(b)(2) candidate for dialysis-related hyperphosphatemia.
FDA discussions center on a pending inspection of a third-party manufacturing vendor cited for deficiencies in a complete response letter.
Approval is targeted in the near term, with launch preparations underway across sales, marketing, reimbursement support, advocacy, logistics.
Company framed hyperphosphatemia as a >USD 1 billion U.S. market, citing more than 550,000 U.S. dialysis patients.
Cash runway is expected into 2027 to support potential FDA clearance and a commercial rollout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on August 16, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia

You may also like

Crypto prices